Letter

Timing of simvastatin treatment: No matter the time of day, does UK policy reflect the evidence?

BMJ 2004; 328 doi: 10.1136/bmj.328.7432.168-b (Published 15 January 2004)
Cite this as: BMJ 2004;328:168.3

Access to the full text of this article requires a subscription or payment. Please log in or subscribe below.

  1. Martin G Duerden (martin@theduerdens.co.uk), senior lecturer in therapeutics,
  2. Maria D Allinson, primary care trust prescribing support pharmacist,
  3. Jo Lockett, senior data analyst
  1. Department of Medicines Management, Keele University, Staffordshire ST5 5BG

    EDITOR—Wallace et al highlight important issues on managing so called hyperlipidaemia.1 The timing of the statin dose is irrelevant, with current policy and practice not designed to deliver the clinical outcomes seen in recent drug trials.2 They studied suboptimal doses, which is common; data from the West Midlands show that 36% of patients are prescribed simvastatin 10 mg …

    Access to the full text of this article requires a subscription or payment

    Subscribe

    Article access

    Article access for 1 day

    Purchase this article for £20 $30 €32*

    The PDF version can be downloaded as your personal record

    * Prices do not include VAT

    Rapid responses

    THIS WEEK'S POLL

    BMJ most popular